In a separate study, tumors from 155 patients with advanced cancers treated with PD-1/PD-L1 inhibitors were evaluated by next-generation sequencing to evaluate potential genomic markers associated with hyperprogressive disease defined as time-to-treatment failure (TTF < 2 months, > 50% increase in tumor burden compared to pre-immunotherapy imaging, and > 2-fold increase in progression pace [71]. Here, CD274 is linked to cancer.